Hoth Agrees with Va. Commonwealth U on Potential Covid Treatment Research

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment.

Research will operate under the direction of Dr. Michael Peters to develop and optimize peptide biomimetics in order to achieve high binding rates of peptide to the RBD of SARS-Cov-2 spike protein at the nanomolar level with demonstrated negligible toxicity through combined computational and experimental efforts. Specifically, point mutations will be conducted in-silico in order to seek to improve the stability and binding properties of these decoy peptides. These optimized, in-silico peptides will be synthesized and experimentally characterized through structure determination, binding to the spike protein, and finally cell challenge assays with SARS-Cov-2.  Hoth Therapeutics has exclusive license to this novel peptide COVID-19 therapeutic.

https://www.biospace.com/article/releases/hoth-therapeutics-announces-sponsored-research-agreement-with-vcu-for-potential-covid-19-treatment/